Skip to main content

Table 1 Patient characteristics

From: Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data

Clinical characteristics

Total (n = 47)

Age, years

  < 70

37 (79%)

  ≥ 70

10 (21%)

Gender

 Male

38 (81%)

 Female

9 (19%)

ECOG PS

 0

12 (25%)

 1

28 (60%)

 2

7 (15%)

Disease status

 Primary metastatic

36 (77%)

 Recurrent

11 (23%)

Histology

 Well or moderately differentiated

21 (45%)

 Poorly differentiated

18 (38%)

 Signet ring cell

4 (9%)

 Combined, others

4 (9%)

HER2 status

 IHC 3+

40 (85%)

 IHC 2+ with SISH +

7 (15%)

Liver metastasis

 No

23 (49%)

 Yes

24 (51%)

Peritoneal metastasis

 No

32 (68%)

 Yes

15 (32%)

Amount of ascites

    No

26 (55%)

 Small or moderate

16 (34%)

 Massive

5 (11%)

Surgical resection

 No

38 (81%)

 Yesa

9 (19%)

  1. ECOG Eastern Cooperative Oncology Group, PS performance status, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, SISH silver-enhanced in situ hybridization
  2. aincluding 6 patients who underwent surgery after chemotherapy